Skip to main content
| Hans-Günter Meyer-Thompson | International

USA. New DEA requirements may limit access to buprenorphine, a popular drug for opioid recovery

USA. New DEA requirements may limit access to buprenorphine, a popular drug for opioid recovery

Doctors and advocates are concerned a federal proposal to roll back a pandemic policy allowing remote prescribing of a common opioid substitute medicine could jeopardize those recovering from addiction. 

With the public health emergency set to end May 11, the Drug Enforcement Administration proposal would require people to visit a doctor or clinic within 30 days of getting a telehealth prescription for buprenorphine. (USA Today, USA, 02.05.2023)

https://eu.usatoday.com/story/news/health/2023/05/02/new-dea-rule-buprenorphine-opioid-epidemic/11715035002/